Stay updated on PCSK9 Inhibition Effect on CV Risk in Treated HIV Clinical Trial
Sign up to get notified when there's something new on the PCSK9 Inhibition Effect on CV Risk in Treated HIV Clinical Trial page.

Latest updates to the PCSK9 Inhibition Effect on CV Risk in Treated HIV Clinical Trial page
- Check4 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference6%
- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check33 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.3%
- Check47 days agoChange DetectedThe web page has been updated to version 2.15.0 from version 2.14.4, indicating a revision in the content. The phrase 'Here’s how you know' has been modified, suggesting a change in the way information is presented.SummaryDifference1.0%
- Check54 days agoChange DetectedThe web page has been updated to a new version (v2.14.4) and the previous version (v2.14.3) has been removed. Additionally, a date of April 6, 2025, has been added.SummaryDifference1%
- Check97 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check112 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference6%
Stay in the know with updates to PCSK9 Inhibition Effect on CV Risk in Treated HIV Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PCSK9 Inhibition Effect on CV Risk in Treated HIV Clinical Trial page.